Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. on October 24, 2014. The filing discloses the entry into a material definitive agreement to establish a joint venture in China.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only specific financial figure disclosed relates to the capitalization of the new joint venture:
- Registered Capital: RMB 2,000,000 (approximately US$326,877.52).
- Capital Contribution Deadline: November 25, 2014.
Material Changes and Agreements
On October 24, 2014, Akers Biosciences, Inc. entered into a Joint Venture Agreement with Hainan Savy Investment Management Ltd. ("Hainan") and Thomas Knox, the Company's Non-Executive Co-Chairman. Key terms include:
- Entity Name: Hainan Savy Akers Biosciences, Ltd.
- Location: Haikou, Hainan, China.
- Purpose: To research, develop, produce, and sell Akers' rapid diagnostic screening and testing products in China, with a focus on diabetes, cardiac, and infectious diseases.
- Ownership Structure:
- Hainan: 56%
- Akers Biosciences, Inc.: 19.9%
- Thomas Knox: 24.1%
- Governance: A Board of Directors will consist of three representatives from Hainan, Raymond F. Akers Jr., Ph.D., and Thomas Knox.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future financial performance, or specific risk factors beyond the inherent nature of entering a new international market. The primary contingency is the requirement for all parties to remit their capital contributions by November 25, 2014.
Investor Verification Checklist
- Verify the execution of the Joint Venture Agreement (Exhibit 10.1) and the specific rights granted to Akers Biosciences.
- Confirm the timeline for the remittance of the US$326,877.52 capital contribution by November 25, 2014.
- Assess the strategic fit of the joint venture's focus on diabetes, cardiac, and infectious disease diagnostics within the Chinese market.
- Review the governance structure to understand Akers' level of control given its minority 19.9% stake.